Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-07
DOI
10.1038/s41598-017-03514-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies
- (2015) Ekaterina V Kurbatova et al. Lancet Respiratory Medicine
- Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South India
- (2014) B. V. Velayutham et al. CLINICAL INFECTIOUS DISEASES
- Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection
- (2014) Andre S. Nell et al. PLoS One
- WHO's 2013 global report on tuberculosis: successes, threats, and opportunities
- (2013) Alimuddin Zumla et al. LANCET
- Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice
- (2013) Priyanka Chauhan et al. Scientific Reports
- Immunotherapy for Tuberculosis: what's the better choice?
- (2012) Shu et al. Frontiers in Bioscience-Landmark
- Adjunct Immunotherapies for Tuberculosis
- (2012) M. Uhlin et al. JOURNAL OF INFECTIOUS DISEASES
- Massive gene acquisitions in Mycobacterium indicus pranii provide a perspective on mycobacterial evolution
- (2012) Vikram Saini et al. NUCLEIC ACIDS RESEARCH
- Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung
- (2012) Ankan Gupta et al. PLoS One
- Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model
- (2012) Ankan Gupta et al. VACCINE
- Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis
- (2011) UD Gupta et al. INDIAN JOURNAL OF MEDICAL RESEARCH
- Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases
- (2010) Payam Tabarsi et al. AMERICAN JOURNAL OF THERAPEUTICS
- Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB
- (2010) Olga V Arjanova et al. Immunotherapy
- Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: A meta-analysis
- (2010) Xiao-yan Yang et al. JOURNAL OF INFECTION
- Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®
- (2009) C. Vilaplana et al. VACCINE
- Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83
- (2008) D-H Yu et al. GENE THERAPY
- Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis
- (2008) K. Katoch et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More